How Did That Lump Get On Your Breast

Barron's Medical Journal Reporting From John Hopkins University Baltimore Md USA

Governors of Texas Greg Abbott And Maryland‘s Larry Hogan Mandate: How Did That Lump Get On Your Breast

Houston ( AP ) --- Barron’s Medical Journal ask the question: How did that lump get on to your breast. B.Bobby Graham Interviewed Rose Conrad Ph.D. Conrad responded with a smile on her face and said let’s open up the breast cancer playbook. Two Companies are leading the way in the personalized medicine space. Genomic Health and Base Health has mastered the science says Barron’s Medical Journal. What is needed is for the newly elected Governors of Texas Greg Abbott And Maryland‘s Larry Hogan to collaborate using Rice University Rice University Institute of Biosciences and Bioengineering and Texas A&M Health Science Center Institute of Biosciences & Technology in Houston. The FDA and a World of Biotech Companies plus National Institute of Health is located in Maryland. Universities like John Hopkins collaborating together can put a end to breast cancer.

Genomic Health, Inc. (NASDAQ: GHDX) is a global cancer company focused on the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.

Over the past decade, we have redefined personalized medicine through the innovation of Oncotype DX, making genomics an indispensable part of breast, colon and prostate cancer diagnosis and treatment. BaseHealth™ makes an integrated health management platform that combines genomic data with clinical and behavioral analysis to engage patients with their physicians in a highly-collaborative way. Our evidence-based assessments help physicians intervene early and often with tailored action plans that span each patient’s unique activity, diet, environmental and lifestyle needs. Personalized medicine starts with a comprehensive understanding of the individual, around whom today’s most successful physicians orient care. This is the first time that a patient can responsibly explore genomic data and non-genomic data in one place, in collaboration with their physician.

Oncogene are genes that take your genes and DNA and convert the your genes to breast cancer genes. The most known gene associated with breast cancer is the KCNK9 Gene. KCNK9 encodes a potassium channel that allows the breast cancer tumor to grow on your breast. This process is aided by Hypoxia. Hypoxia refers to an inadequate oxygen supply to the cells and tissues of the Breast. The Main Gene that stops the growth of KCNK9 Genes is gene is p53. p53 is a fundamental determinant of cancer susceptibility, p53 integrates stress signals and elicits apoplectic responses that maintain genomic stability.

In 2006 and 2007, promising to take customers’ DNA and create personalized health reports to help us understand the medical risks lurking in our genomes, the pressures facing genomic health services seemed clear. Sequencing a human genome was prohibitively expensive, coming in at well over a million dollars — would they be able to narrow down their DNA targets enough to come in at an attractive price point, while still collecting useful information? Would the FDA and other regulators smile on these products, or regard them as unproven medical tests? Was there even a market for DNA data?

Fast forward to today, and the whole business of genomic health looks very different indeed. The genome is a commodity within reach of the middle class, coming in at the price of a cheap used car. Genetic health reports are decidedly “medical devices,” and the FDA is vocally worried that consumers could be dangerously misinformed if providers don’t go through a careful regulatory process.

When cells sense a decrease in oxygen availability (hypoxia), they develop adaptive responses in order to sustain this condition and survive. If hypoxia lasts too long or is too severe, the cells eventually die. Hypoxia is also known to modulate the p53 pathway, in a manner dependent or not of HIF-1 (hypoxia-inducible factor-1), the main transcription factor activated by hypoxia. The p53 protein is a transcription factor, which is rapidly stabilized by cellular stresses and which has a major role in the cell responses to these stresses. This process is why it is important Conrad says for people that are first degree relatives of breast cancer patients, must take a genomic test to see if they are the carrier of gene KCNK9. By identifying this gene we can direct patients with the correct advise as to deal with the fact that they have a lunp on the breast to they are going to get a lump on their breast. Often what happens is that a breast cancer patients dose not go to the doctor or take important test to see if there is a lump on the breast. what happens is the spread of breast cancer is responsible for more than 90 percent of breast cancer deaths. The process by which breast cancer spreads — or metastasizes is where Metastasis was long thought as a late event in breast cancer progression, With Genomics we now shown metastasis to be an early event that is dependent on Hypoxia HIF-1. HIF-1 protein controls genes that enable cells to survive in low oxygen, like cells in solid breast tumors. In order for breast cancer cells to spread to lungs, they must leave the breast,enter blood vessels that lead to the lungs, and exit those same vessels. “

Blood vessels are pretty tight; a cell has to work pretty hard to get through the vessel wall. How this process works is breast cancer cells turn on genes called ANGPTL4, ANGPTL4, helps breast cancer to travel through blood vessel walls. Research is now being performed with Genomics. The Gennxeix Biotech Team found by injecting these cells either with normal or “knocked-down” levels of ANGPTL4 into mice and examining their lungs. Cells lacking HIF-1 and containing extra ANGPTL4 were better able to invade the lungs than cells without extra ANGPTL4. There are other genes that are involved in the creation of a breast cancer tumor on the breast. Her-2, p63, 73. Conrad goes on to say that in their genomic test uses 21 different genes to project ,stop the growth and the spread of a patients breast cancer Lump. HIF-1 as a therapeutic target can extend the life of many stage four breast Cancer patients.
Gennxeix discovered The tumor suppressors VHL (von Hippel-Lindau protein) and p53 target HIF-1α for ubiquitination to inactivation breast cancer tumors cells increases the of HIF-1. This process Increased phosphatidylinositol 3-kinase (PI3K) and AKT.

In breast cancer, increased activity of the HER2 (also known as neu) receptor tyrosine kinase is associated with increased tumor grade, chemotherapy resistance, and decreased patient survival. HER2 has also been implicated as an inducer of VEGF expression. GenNXeix demonstrate that HER2 signaling induced by over expression in mouse 3T3 cells or human MCF-7 breast cancer cells results in increased HIF-1α protein and VEGF mRNA expression that is dependent upon activity of PI3K, AKT (also known as protein kinase B), and the downstream kinase FRAP (KBPS-rapamycin-associated protein)
Gennxeix concern with patients with diabetes and breast cancer may not receive full Benefit of HIF-1. All women having access to a physician can have access to HIF-1 treatments